ARQT Stock Analysis: Arcutis Biotherapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.261m USD | 12M Return: 106.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.4M
Qual. Beats: 0
Rev. Trend: 92.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arcutis Biotherapeutics (NASDAQ: ARQT) is a U.S.-based, mid-cap biopharmaceutical company founded in 2016 and headquartered in Westlake Village, California. The company specializes in developing and commercializing topical treatments for dermatological diseases, with its lead product ZORYVE (roflumilast cream) approved for plaque psoriasis and atopic dermatitis. Its pipeline also includes a ZORYVE foam formulation targeting seborrheic dermatitis, scalp and body psoriasis, as well as ARQ-234, a CD200 receptor fusion protein in earlier-stage development. The company rebranded from Arcutis, Inc. to its current name in October 2019 and went public on NASDAQ in January 2020.
As a clinical-stage-to-commercial dermatology biotech, Arcutis operates within the highly R&D-intensive biotechnology sub-industry of the broader Health Care sector, where companies typically depend on a small number of approved products or pipeline candidates for revenue. The companys focus on topical therapeutics for skin conditions represents a targeted niche within dermatology, an area characterized by large patient populations but competitive generic and branded alternatives.
- ZORYVE cream revenue scales with atopic dermatitis label expansion
- Competition from oral JAK inhibitors pressures topical psoriasis market share
- Cash burn raises dilution risk as commercialization spending outpaces product revenue
| Net Income: -2.38m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 39.76 > 1.0 |
| NWC/Revenue: 66.13% < 20% (prev 109.3%; Δ -43.14% < -1%) |
| CFO/TA 0.06 > 3% & CFO 27.0m > Net Income -2.38m |
| Net Debt (-109.3m) to EBITDA (15.0m): -7.28 < 3 |
| Current Ratio: 2.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (129.4m) vs 12m ago 2.64% < -2% |
| Gross Margin: 90.94% > 18% (prev 88.39%; Δ 2.55% > 0.5%) |
| Asset Turnover: 103.4% > 50% (prev 61.85%; Δ 41.53% > 0%) |
| Interest Coverage Ratio: 0.90 > 6 (EBIT TTM 12.1m / Interest Expense TTM 13.5m) |
| A: 0.60 (Total Current Assets 438.1m - Total Current Liabilities 163.2m) / Total Assets 460.0m |
| B: -2.50 (Retained Earnings -1.15b / Total Assets 460.0m) |
| C: 0.03 (EBIT TTM 12.1m / Avg Total Assets 402.1m) |
| D: 0.70 (Book Value of Equity 189.6m / Total Liabilities 270.4m) |
| Altman-Z'' = -3.29 = D |
| DSRI: 0.87 (Receivables 144.4m/85.4m, Revenue 415.6m/212.8m) |
| GMI: 0.97 (GM 88.39% / 90.94%) |
| AQI: 0.72 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 1.95 (Revenue 415.6m / 212.8m) |
| TATA: -0.06 (NI -2.38m - CFO 27.0m) / TA 460.0m) |
| Beneish M = -2.65 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 27.67 with a total of 2,396,772 shares traded. Over the past week, the price has changed by +3.40%, over one month by +28.46%, over three months by +18.91% and over the past year by +106.65%.
Current recommended Stop Loss: 26.30 (which is 5% or 1.3 ATR below the current price).
Arcutis Biotherapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy ARQT.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 34.6 | 25.2% |
P/E Forward = 142.8571
P/S = 7.8459
P/B = 17.0165
Revenue TTM = 415.6m USD
EBIT TTM = 12.1m USD
EBITDA TTM = 15.0m USD
Long Term Debt = 101.5m USD (from longTermDebt, last quarter)
Short Term Debt = 7.95m USD (from shortTermDebt, last quarter)
Debt = 114.7m USD (corrected: LT Debt 101.5m + ST Debt 7.95m) + Leases 5.25m
Net Debt = -109.3m USD (calculated: Debt 114.7m - CCE 224.0m)
Enterprise Value = 3.15b USD (3.26b + Debt 114.7m - CCE 224.0m)
Interest Coverage Ratio = 0.90 (Ebit TTM 12.1m / Interest Expense TTM 13.5m)
EV/FCF = 117.1x (Enterprise Value 3.15b / FCF TTM 26.9m)
FCF Yield = 0.85% (FCF TTM 26.9m / Enterprise Value 3.15b)
FCF Margin = 6.48% (FCF TTM 26.9m / Revenue TTM 415.6m)
Net Margin = -0.57% (Net Income TTM -2.38m / Revenue TTM 415.6m)
Gross Margin = 90.94% ((Revenue TTM 415.6m - Cost of Revenue TTM 37.6m) / Revenue TTM)
Gross Margin QoQ = 90.72% (prev 90.97%)
Tobins Q-Ratio = 6.85 (Enterprise Value 3.15b / Total Assets 460.0m)
Interest Expense / Debt = 11.75% (Interest Expense 13.5m / Debt 114.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 9.54m (EBIT 12.1m * (1 - 21.00%))
Current Ratio = 2.68 (Total Current Assets 438.1m / Total Current Liabilities 163.2m)
Debt / Equity = 0.60 (Debt 114.7m / totalStockholderEquity, last quarter 189.6m)
Debt / EBITDA = -7.28 (Net Debt -109.3m / EBITDA 15.0m)
Debt / FCF = -4.06 (Net Debt -109.3m / FCF TTM 26.9m)
Total Stockholder Equity = 169.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.59% (Net Income -2.38m / Total Assets 460.0m)
RoE = -1.41% (Net Income TTM -2.38m / Total Stockholder Equity 169.0m)
RoCE = 4.46% (EBIT 12.1m / Capital Employed (Equity 169.0m + L.T.Debt 101.5m))
RoIC = 3.36% (NOPAT 9.54m / Invested Capital 284.0m)
WACC = 8.85% (E(3.26b)/V(3.38b) * Re(8.84%) + D(114.7m)/V(3.38b) * Rd(11.75%) * (1-Tc(0.21)))
Discount Rate = 8.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 16.03%
[DCF] Terminal Value 73.68% ; FCFF base≈26.9m ; Y1≈27.0m ; Y5≈28.6m
[DCF] Fair Price = 4.15 (EV 410.1m - Net Debt -109.3m = Equity 519.4m / Shares 125.1m; r=8.85% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.23 | # QB: 0
Revenue Correlation: 92.93 | Revenue CAGR: 188.2% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.05 | Chg30d=-28.15% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.09 | Chg30d=-35.80% | Revisions=-17% | Analysts=5
EPS current Year (2026-12-31): EPS=0.24 | Chg30d=-33.26% | Revisions=-17% | GrowthEPS=+288.5% | GrowthRev=+32.2%
EPS next Year (2027-12-31): EPS=1.16 | Chg30d=-9.61% | Revisions=-50% | GrowthEPS=+371.7% | GrowthRev=+29.9%
[Analyst] Revisions Ratio: -36% (up=3, down=8)